ARA-290 (cibinetide): an EPO-derived peptide agonist of the innate repair receptor

RUO: for laboratory research only. This material describes the chemistry, molecular mechanism and published research record of ARA-290 and contains no guidance for human use.

ARA-290 (International Nonproprietary Name cibinetide) is a synthetic linear 11-amino-acid peptide developed as a non-erythropoietic, tissue-protective analogue of erythropoietin (EPO). It reproduces a restricted region of the EPO molecular surface responsible for tissue protection, while lacking the ability to stimulate red-cell production. ARA-290 became the prototype of the "innate repair receptor (IRR) agonist" class and one of the most thoroughly studied tools for dissecting the non-erythropoietic functions of EPO in models of inflammation and nerve injury.

Discovery and background

The classical role of EPO is to stimulate erythropoiesis via the homodimeric EPOR on erythroid progenitor cells. From the late 1990s, however, evidence accumulated that EPO protects neurons, cardiomyocytes and renal epithelium under ischemia and inflammation. A key step was the demonstration that this tissue-protective action is mediated not by the EPOR homodimer but by a heterocomplex of EPOR with the common β-subunit of cytokine receptors (β-common receptor, βcR / CD131), whose expression is induced in response to tissue injury ^[1]. Because systemic EPO at protective doses is hazardous owing to enhanced erythropoiesis, thrombosis and hypertension, the goal became to separate the protective activity from the hematopoietic one. Analysis of the EPO tertiary structure showed that the erythropoietic determinants cluster around helices A and C, whereas the tissue-protective signal is associated with helix B. On this basis a series of short peptides mimicking the aqueous face of helix B was engineered; the most active proved to be an 11-mer designated ARA-290 ^[2]. Conceptually, these works framed the idea of "the receptor that tames the innate immune response", an innate repair receptor triggered locally in injured tissue that shifts the inflammatory reaction toward resolution and repair ^[3].

Structure and physicochemistry

ARA-290 is a linear peptide with the sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (the N-terminal residue is pyroglutamate, 5-oxo-L-proline). Molecular formula C51H84N16O21, molar mass ≈1257.3 g/mol, CAS (Chemical Abstracts Service number) 1208243-50-8, UNII 9W5677JKDA. The sequence corresponds to the aqueous-facing (hydrophilic) residues of helix B of native human EPO ^[2]. The peptide is highly soluble in water and polar buffers owing to its numerous charged and polar side chains (two glutamates, an arginine, an asparagine, two serines); the N-terminal pyroglutamate increases resistance to aminopeptidases relative to a free N-terminus. The molecule contains no cysteines, so it forms no disulfide bridges and is not prone to oxidative oligomerization; the C-terminal Asn-Ser-Ser fragment, however, is potentially susceptible to deamidation under alkaline conditions.

Molecular mechanism: the innate repair receptor

The functional target of ARA-290 is not the homodimeric EPOR but a heteromeric innate repair receptor formed by at least one EPOR subunit in complex with the β-common receptor (CD131/CSF2RB) ^[1][3]. It is the βcR-containing complex, rather than the erythroid EPOR, that bridges the EPO-like signal to an anti-inflammatory/reparative program. ARA-290 selectively activates the IRR while binding negligibly to the classical erythropoietic receptor, which accounts for the absence of an erythropoietic effect alongside preserved tissue protection ^[2][4]. IRR expression is induced locally by pro-inflammatory mediators and metabolic stress, so the agonist acts predominantly at the site of injury rather than systemically, a fundamental difference from native EPO ^[4].

Signaling and downstream effects

Activation of the IRR engages the same protein kinases as the EPO survival signal, but without the erythropoietic arm. Reported involvement includes JAK2 with subsequent phosphorylation of STAT3 (and, to a lesser degree, STAT5), activation of the PI3K/Akt axis and the ERK1/2 cascade. Through these pathways ARA-290 raises levels of anti-apoptotic proteins (notably Bcl-xL), activates endothelial NO synthase (eNOS), suppresses NF-κB signaling and pro-inflammatory cytokine production, reduces apoptosis and promotes the transition of inflammation toward resolution ^[4]. The consequences are stabilization of the microvascular bed, limitation of secondary ("collateral") damage after the primary injury, and support of nerve and epithelial regeneration ^[4].

Preclinical research

Neuropathic pain became one of the most instructive models. In rats, ARA-290 produced long-lasting relief of behavioral signs of neuropathic pain after nerve injury, and the effect was completely abolished in β-common receptor knockout mice, direct genetic confirmation that the action is mediated specifically by the βcR-containing IRR ^[5]. In acute myocardial infarction models the peptide reduced infarct size and improved left-ventricular function, reproducing the cardioprotective profile of EPO without raising hematocrit ^[6]. In a cutaneous burn model ARA-290 prevented secondary microvascular thrombosis and inflammation, limiting the depth of burn-wound progression ^[7]. In a renal ischemia-reperfusion model, cibinetide attenuated acute kidney injury by reducing inflammation and tubular-epithelial apoptosis ^[8]. Together these studies outline a broad organ-protective spectrum whose common denominator is suppression of an excessive innate inflammatory response.

Clinical and human research (as literature)

ARA-290 has been studied primarily in small-fiber nerve disorders. In a randomized, double-blind pilot study in patients with sarcoidosis-associated small-fiber neuropathy symptoms, the peptide showed an acceptable tolerability profile and a positive signal on symptoms ^[9]. A subsequent report described symptom improvement together with an increase in corneal nerve-fiber density (by corneal confocal microscopy), an objective morphological marker of small-fiber regeneration ^[10]. In patients with type 2 diabetes, investigators described improved metabolic parameters and reduced neuropathic symptoms ^[11]. Review and programmatic publications consolidated the concept of targeting the IRR to treat neuropathy and framed a research agenda for further trials ^[12]. These data belong to the published research record; they are not guidance for use.

Pharmacokinetics and metabolism

As a short linear peptide with no stabilizing modifications beyond the N-terminal pyroglutamate, ARA-290 has a very brief plasma residence: its circulatory half-life is estimated on the order of a few minutes, with elimination occurring mainly through proteolysis and renal clearance. Despite this, the biological effect long outlives the peptide's presence in blood: transient IRR activation triggers intracellular reparative programs whose consequences persist far beyond the pharmacokinetic exposure ("flipping the molecular switch") ^[4][12]. Crucially, ARA-290 does not stimulate erythropoiesis or raise hematocrit and therefore does not share the thrombotic and hemodynamic risks inherent to high-dose EPO ^[4].

Related compounds and analogues

ARA-290 belongs to the family of non-erythropoietic EPO derivatives. Historically, the first were chemically modified forms of the full-length protein: carbamylated EPO (CEPO) and asialo-EPO, which retained tissue-protective activity while losing or reducing the erythropoietic one ^[1][2]. The next step was short helix-B peptides: ARA-290 itself and the related helix B surface peptide (HBSP) and its pyroglutamate-stabilized form (pHBSP/ARA-290 in the broader nomenclature), used in particular in models of renal ischemia-reperfusion injury ^[8]. The shared feature of the class is IRR activation without engaging the erythroid EPOR.

Analytical characterization

The identity and purity of ARA-290 are confirmed by reversed-phase HPLC (RP-HPLC, detection at 214/220 nm) combined with mass spectrometry (ESI-MS), where the expected monoisotopic/average mass corresponds to ≈1257.3 Da for the protonated ions; MS/MS fragmentation allows verification of the sequence and of the N-terminal pyroglutamate. Research-grade lots typically declare a chromatographic purity of >95%, along with determination of peptide content (by nitrogen or amino-acid analysis), residual trifluoroacetate as the synthesis counterion, and a related-impurity profile (deamidated and truncated forms). Capillary electrophoresis and amino-acid composition analysis after acid hydrolysis serve as orthogonal control methods.

Handling, reconstitution chemistry and storage

ARA-290 is supplied as a lyophilized powder. Owing to its hydrophilicity, the peptide reconstitutes readily in sterile or bacteriostatic water or dilute aqueous buffers; where needed, a small amount of dilute acetic acid is used for more complete dissolution. The lyophilizate is stored frozen and protected from moisture; reconstituted solutions are unstable at room temperature and should be aliquoted, minimizing freeze-thaw cycles that promote aggregation and deamidation of the sensitive Asn/Ser residues. Working solutions are protected from repeated thawing and from prolonged alkaline conditions.

Research applications and model systems

In basic research ARA-290 is used as a selective pharmacological probe to separate the erythropoietic from the tissue-protective arm of EPO signaling. The key genetic control is the β-common receptor knockout mouse, in which the peptide's effect disappears, demonstrating receptor specificity ^[5]. The standard model set spans neuropathic pain after peripheral nerve injury ^[5], acute myocardial infarction ^[6], cutaneous burn injury ^[7], and renal ischemia-reperfusion ^[8], as well as streptozotocin models of diabetic neuropathy. In these systems ARA-290 is applied to study mechanisms of inflammation resolution, cell survival and microvascular remodeling, making it a useful tool for interrogating the biology of the innate repair receptor.